ライフサイエンスコーパス: mevastatin

1 was abrogated by simultaneous treatment with mevastatin.

2 continued to proliferate in the presence of mevastatin.

3 rol depletion by methyl-beta-cyclodextrin or mevastatin.

4 reated with the HMG-CoA reductase inhibitor, mevastatin (1-10 microM), in the presence of L-mevalonat

5 AEC pretreated with mevastatin, a specific inhibitor of prenylation, or tran

6 We conclude that topical mevastatin accelerates wound closure by promoting epithe

7 Mevastatin also caused apoptosis in both wild-type and p

8 d epithelialization and angiogenesis in vivo Mevastatin also reversed FPP-mediated induction of the G

9 trin, which reversibly binds cholesterol, or mevastatin, an inhibitor of cholesterol biosynthesis, to

10 Mevastatin, an inhibitor of cholesterol synthesis, inhib

11 erol and sphingomyelin synthesis inhibitors (mevastatin and myriocin, respectively), suggesting that

12 Both mevastatin and simvastatin caused a concentration- and t

13 bserved after treatments with brefeldin A or mevastatin and when the conserved isoprenylation sequenc

14 The statins mevinolin and mevastatin are weak inhibitors of L. monocytogenes HMG-C

15 Mevastatin arrested HCT116 colon cancer cells at the G1/

16 Mevastatin blocked cholesterol accumulation in injured H

17 We find that mevastatin does not appear to be a substrate for hCE1, a

18 rosuvastatin = simvastatin > atorvastatin = mevastatin > pravastatin, which is similar to the known

19 Mevastatin increased eNOS mRNA and protein levels by 305

20 In p27Kip1-deficient PASMCs, mevastatin induced a greater reduction of cyclin E prote

21 We found that mevastatin induced G1 arrest and decreased DNA synthesis

22 eletion and mutational analyses suggest that mevastatin induced KLF2 promoter activity through a sing

23 ly rescued primary rat cortical neurons from mevastatin-induced neurotoxicity.

24 ured cortisol levels by ELISA and found that mevastatin inhibited cortisol synthesis in keratinocytes

25 [35S]GTPgammaS-binding assays revealed that mevastatin inhibited Rho membrane translocation and GTP

26 Using RNA interference we show that mevastatin inhibits cdk2 activity despite lack of induct

27 These results suggest that mevastatin inhibits cdk2 activity in PC3 cells through t

28 Mevastatin is an inhibitor of 3-hydroxy-3-methylglutaryl

29 G1/S arrest of HCT116 colon cancer cells by mevastatin, its mode of action was more complicated than

30 of this study was to determine the effect of mevastatin on DNA synthesis, cell cycle progression, and

31 Treatment of these AMLs with mevastatin or zaragozic acid (which inhibits cholesterol

32 Importantly, mevastatin reversed c-Myc overexpression in DFUs.

33 onstrate that the naturally occurring statin mevastatin reverses FPP's effects and promotes healing b

34 lonate or GGPP, but not FPP or LDL, reversed mevastatin's effects.

35 wever, in PASMCs lacking functional p27Kip1, mevastatin still decreased cyclin E kinase activity, cau

36 Of note, topical mevastatin stimulated epithelialization and angiogenesis

37 ctivating kinase, Cak), was not inhibited by mevastatin, suggesting either that a different CAK is re

38 complexes with the cholesterol-lowering drug mevastatin, the breast cancer drug tamoxifen, the fatty

39 Treatment of 293 cells with mevastatin to deplete cellular mevalonate resulted in an

40 n of KLF2 strongly attenuated the ability of mevastatin to increase eNOS and thrombomodulin accumulat

41 important role for p27Kip1 in the ability of mevastatin to induce G1 arrest.

42 Phosphorylation of cdk2 from mevastatin-treated cells with exogenous cyclin-dependent

43 bition of both pathways simultaneously using mevastatin-treated Ldlr(-/-) cells did inhibit forskolin

44 cells, or of cholesterol biosynthesis, using mevastatin-treated WT cells, failed to inhibit matrix mi

45 In a prostate cancer cell line, PC3, mevastatin treatment led to elevated levels of p21 and c

46 Apoptosis induced by bisphosphonate or mevastatin was found to be dependent on protein synthesi

47 oxy-3-methylglutaryl-CoA-reductase inhibitor mevastatin, which blocks FPP formation, not only promote

48 bset of patients and grown in 0.5% serum and mevastatin with increasing amounts of recombinant PCSK9.